IMAC Holdings (BACK) Stock Price, News, Quotes-Moomoo

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Ignite Proteomics, Subsidiary Of IMAC Holdings, Announces MHC-II Expression As Superior Predictor For Pembrolizumab Response Compared To PD-L1 Ahead Of NCCN Conference
BenzingaFeb 24 08:18 ET
Ignite Proteomics to Present Data on MHC-II as a Predictor of Pembrolizumab Response at NCCN Annual Conference
GlobeNewswireFeb 24 08:15 ET
Ignite Proteomics Completes Acquisition of PLA Code 0249U for Its Advanced Proteomic Breast Cancer Assay
GlobeNewswireFeb 19 09:15 ET
Ignite Proteomics Publishes Study In British Journal of Cancer Titled "Functional Activation of the AKT–mTOR Signalling Axis in a Real-world Metastatic Breast Cancer Cohort"
BenzingaFeb 10 09:17 ET
Ignite Proteomics Announces Publication of Study Demonstrating Superiority of Protein Activation Analysis in Predicting Breast Cancer Therapy Response
GlobeNewswireFeb 10 09:15 ET
US Stocks Mixed; General Dynamics Earnings Top Views
BenzingaJan 29 10:10 ET

Comments

Trytosaveabit

Feb 24 07:19

Update

$IMAC Holdings (BACK.US)$ Ignite Proteomics to Present Data on MHC-II as a Predictor of Pembrolizumab Response at NCCN Annual Conference
2 MINUTES AGO, 8:15 AM EST
VIA GLOBENEWSWIRE
Golden, CO, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Ignite Proteomics LLC, a subsidiary of IMAC Holdings, Inc. (NASDAQ:BACK), today announced the presentation of new data demonstrating that MHC-II protein expression is a superior predictor of response to pembrolizumab (Keytruda®) compared to PD-L1 at the upcoming Nati...

Trytosaveabit

Feb 19 08:26

News

$IMAC Holdings (BACK.US)$ Ignite Proteomics Completes Acquisition of PLA Code 0249U for Its Advanced Proteomic Breast Cancer Assay
GlobeNewswire· 5 mins ago
Golden, CO, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Ignite Proteomics LLC, a subsidiary of IMAC Holdings, Inc. (Nasdaq: BACK), today announced the completed transfer of Proprietary Laboratory Analyses (PLA) code 0249U – originally issued to Theralink Technologies, Inc. – to Ignite Proteomics LLC. The AMA CPT code is listed on the Medicare Clini...

Jaguar8

Feb 10 08:15

NEWS

$IMAC Holdings (BACK.US)$
Ignite Proteomics Announces Publication of Study Demonstrating Superiority of Protein Activation Analysis in Predicting Breast Cancer Therapy Response
Monday, 10th February at 9:15 am
The new study adds to growing evidence that measuring activated proteins is key to cancer therapy selection.
Golden, CO, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Ignite Proteomics LLC, a subsidiary of IMAC Holdings, Inc. (NASDAQ: BACK), announces the publication of a significant study in the B...

2

1